Cohort Profile: The Canadian HIV-Hepatitis C Co-infection Cohort Study

Marina B. Klein, Sahar Saeed, Hong Yang, +14

International Journal of Epidemiology

Hepatitis C VirusImmunologyHepatitis BViral HepatitisChronic Viral Infection +15

1359 FIRST SVR DATA WITH THE NUCLEOSIDE ANALOGUE POLYMERASE INHIBITOR MERICITABINE (RG7128) COMBINED WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE HCV G1/4 PATIENTS: INTERIM ANALYSIS FROM THE JUMP-C TRIAL

Paul J. Pockros, Dorte Møller Jensen, N. Tsai, +9

Journal of Hepatology

Interim AnalysisThe Jump-c TrialViral HepatitisAntiviral Drug DevelopmentAntiviral Therapy +4

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3

Jeff Powis, Kevork Peltekian, Shoei‐Sheng Lee, +8

Journal of Viral Hepatitis

50 BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN FOR THE TREATMENT OF HCV/HIV CO-INFECTED PATIENTS: END OF TREATMENT (WEEK 48) INTERIM RESULTS

Josep Mallolas, Stanislas Pol, Antonio Rivero, +7

Journal of Hepatology

Viral HepatitisWeek 48Antiviral Drug DevelopmentAntiviral TherapyHepatitis +8

Factors Associated With Discordance Between Absolute CD4 Cell Count and CD4 Cell Percentage in Patients Coinfected With HIV and Hepatitis C Virus

Mark Hull, K. Rollet, Adefowope Odueyungbo, +5

Clinical Infectious Diseases

ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials

Massimo Puoti, C. Cooper, Sulkowski, +9

Queen Mary Research Online (Queen Mary University of London)

Treatment And PreventionViral HepatitisAntiviral Drug DevelopmentAntiviral TherapyHepatitis +6

940 SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE HCV POLYMERASE INHIBITOR VCH-222 FOLLOWING SINGLE DOSE ADMINISTRATION IN HEALTHY VOLUNTEERS AND ANTIVIRAL ACTIVITY IN HCV-INFECTED INDIVIDUALS

C. Cooper, Richard Larouche, B. Bourgault, +2

Journal of Hepatology

Viral HepatitisAntiviral Drug DevelopmentTolerability And PharmacokineticsHepatitisVirology +4

The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study

Marina B. Klein, Jim Young, David Dunn, +12

CMAJ Open

1177 RAPID AND SUSTAINED ACHIEVEMENT OF UNDETECTABLE HCV RNA DURING TREATMENT WITH RITONAVIR-BOOSTED DANOPREVIR/PEG-IFNa-2A/RBV IN HCV GENOTYPE 1 OR 4 PATIENTS: DAUPHINE WEEK 12 INTERIM ANALYSIS

Greg Everson, C. Cooper, Christophe Hézode, +12

Journal of Hepatology

Interim AnalysisDiagnostic VirologyHepatitis CViral HepatitisImmunology +8

Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials

J. Grebley, Massimo Puoti, Heiner Wedemeyer, +11

Journal of Hepatology

Opioid EpidemicViral HepatitisMedicineClinical TrialsHepatitis +9